Bingham Osborn & Scarborough’s Gilead Sciences GILD Stock Holding History

Bingham Osborn & Scarborough’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,864	Closed	-$200K	–	55
2021 Q3	$200K	Buy	+2,864	New	+$201K	0.01%	156
2016 Q3	–	Sell	-3,867	Closed	-$323K	–	113
2016 Q2	$323K	Sell	3,867 -14	-0.4%	-$1.24K	0.04%	89
2016 Q1	$357K	Buy	3,881 +3	+0.1%	+$271	0.04%	85
2015 Q4	$392K	Hold	3,878	–	–	0.05%	77
2015 Q3	$381K	Sell	3,878 -608	-14%	-$67.5K	0.05%	75
2015 Q2	$525K	Hold	4,486	–	–	0.06%	66
2015 Q1	$440K	Hold	4,486	–	–	0.05%	72
2014 Q4	$423K	Sell	4,486 -480	-10%	-$49.6K	0.05%	75
2014 Q3	$529K	Buy	4,966 +480	+11%	+$47K	0.07%	70
2014 Q2	$372K	Sell	4,486 -200	-4%	-$15.6K	0.05%	71
2014 Q1	$332K	Sell	4,686 -550	-11%	-$43.1K	0.05%	76
2013 Q4	$393K	Hold	5,236	–	–	0.06%	65
2013 Q3	$329K	Hold	5,236	–	–	0.05%	65
2013 Q2	$268K	Buy	+5,236	New	+$273K	0.05%	67

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bingham Osborn & Scarborough's GILD Position: Q4 2021 in Review

Bingham Osborn & Scarborough sold out of Gilead Sciences (GILD) in Q4 2021, closing a stake of 2,864 shares — an estimated $200K sold.

Bingham Osborn & Scarborough first reported a position in GILD in Q2 2013 and held it in 14 quarters. The position peaked at $529K in Q3 2014. 1,682 funds tracked by Wall St. Rank hold GILD as of Q4 2021.

Bingham Osborn & Scarborough reported no remaining Gilead Sciences position as of Q4 2021 after selling out during the quarter.
Bingham Osborn & Scarborough sold 2,864 Gilead Sciences shares in Q4 2021, an estimated $200K.
Bingham Osborn & Scarborough first reported a position in Gilead Sciences in Q2 2013 and held it in 14 quarters.
Bingham Osborn & Scarborough's Gilead Sciences position peaked at $529K in Q3 2014.
1,682 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2021.

Based on Bingham Osborn & Scarborough's 13F filing for Q4 2021.